Related Experiment Video
Updated: Jun 30, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Assessing the value-adding impact of diagnostic-type tests on drug development and marketing
1Integrated Medicines Ltd, Cambridge, England. eddie.blair@integratedmedicines.co.uk
Objective And Methods:
We explore the cash value of the companion diagnostics opportunity from the perspective of the pharmaceutical partner. Cashflow-based modeling is used to demonstrate the potential financial benefits of key relationships between the pharmaceutical and diagnostics industries.
Results:
In four scenarios, the uplift in the net present value (NPV) of a proprietary medicine can exceed $US1.8 billion. By simple extrapolation, the uplifted NPV calculations allow realistic and plausible estimates of the companion diagnostic opportunity to be in the region of $US40 billion to $US90 billion.
Conclusion:
It is expected that such market valuation could drive a macroeconomic change that shifts healthcare practice from reactionary disease-treatment to proactive health maintenance.
Related Concept Videos
Clinical Trials: Overview
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Preclinical Development: Overview
Automated Microbial Diagnostics
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Drug Analysis Methods

